Background: Mutations in the leucine-rich, gliomainactivated 1 (LGI1) gene have been implicated in autosomal dominant lateral temporal epilepsy.
A
LTHOUGH TEMPORAL LOBE epilepsy has been traditionally regarded as an acquired symptomatic disorder, evidence for familial temporal lobe epilepsy has been described. 1 One form is autosomal dominant lateral temporal epilepsy (ADLTE) which is caused by mutations in the LGI1 (leucine-rich, glioma-inactivated 1) gene. 2, 3 The clinical hallmark of seizures in some patients is an auditory aura, which can be triggered by external noises. Ictal manifestations may include aphasic, visual, or pseudovertiginous symptoms, suggesting involvement of the lateral temporal lobe or adjacent cortical areas. 4 Autosomal dominant lateral temporal epilepsy represents a benign clinical entity that is probably underestimated because the simple partial seizures are mild.
In 2002, the first LGI1 mutations were identified in families with ADLTE, 2, 3 followed by the description of many other mutations, 5 including a de novo nonsense mutation. 6 LGI1 encodes a neuronal protein also known as epitempin. 3 The N-terminus has a signal peptide followed by 4 1 ⁄2 leucinerich repeats. The C-terminus consists of 7 tandem epilepsy-associated repeats (EARs) also identified in monogenic audiogenic seizures susceptibility protein (MASS1), which is mutated in a mouse line with audiogenic epilepsy. 7, 8 Although LGI1 was originally identified as a candidate tumor suppressor gene in gliomas, 9 its role in brain tumors remains controversial. 10 In addition, LGI1 is secreted to the extracellular environment by 293T cells. 11, 12 Unexpectedly, cytosolic LGI1 was recently shown to prevent inactivation of the presynaptic voltage-gated potassium channel subunit Kv1.1. 13 We report herein 2 novel LGI1 mutations, p.Leu232Pro and c.431ϩ1GϾA, in 2 families with ADLTE. Our functional investigations provide evidence that both mutations are deleterious and that in Chinese hamster ovary (CHO) and rat adrenal pheochromocytoma 12 (PC12) cells LGI1 is secreted to the extracellular environment.
METHODS

FAMILIES
Six families with partial epilepsy were selected for this study on the basis of the following characteristics: (1) At least 1 affected subject had auditory ictal symptoms. (2) Cerebral magnetic resonance imaging was normal in at least the proband. (3) There were affected individuals in several generations compatible with autosomal dominant inheritance. In family B, however, there were several loops of consanguinity that would also be compatible with a recessive mode of transmission. Blood samples were obtained with informed consent, and genomic DNA was extracted using standard procedures.
LGI1 MUTATION SCREENING
Mutation analysis was performed in 1 index case from each of the 6 families with ADLTE by direct sequencing of all 8 LGI1-coding exons and flanking intronic splice sites. Primer sequences for the polymerase chain reaction (PCR) are available from us on request. Polymerase chain reaction products were sequenced using a sequence detection system (Big Dye Terminator Cycle, ABI PRISM; Applied Biosystems, Norwalk, Conn).
REVERSE TRANSCRIPTION AND PCR
We isolated total RNA from lymphoblasts of patient II-3 and from transfected CHO cells (RNeasy Miniprep; Qiagen, Studio City, Calif). The corresponding complementary DNA (cDNA) was obtained by oligo-dT-primed reverse transcription (Thermoscript; Invitrogen, San Diego, Calif). Exons 1 to 5 were then amplified by PCR, followed by a nested PCR because of the low abundance of LGI1 messenger RNA (mRNA) in lymphoblasts.
CELL CULTURE AND TRANSFECTION
Using full-length mouse wild-type LGI1 cDNA with a FLAG tag at the N-terminus, LGI1
E383A and LGI1 L232P were generated using a commercially available kit (Quickchange; Stratagene, La Jolla, Calif ). CHO and PC12 cells were cultured in Dulbecco modified Eagle medium containing 10% fetal bovine serum, 10 U/mL of penicillin G sodium, and 10 µg/mL of streptomycin sulfate. All transient transfections were performed according to the manufacturer's recommendations (Lipofectamine 2000, Invitrogen), followed by a 14-to 16-hour incubation of serum-free media. The cells and media were analyzed 24 to 36 hours after transfection. Cell lysates and conditioned media were prepared as previously described, 12 and total protein concentrations were determined using the Bradford 14 method. Twenty-five micrograms of each sample was separated on 10% Tris-glycine polyacrylamide gels, analyzed by Western blot (WB) using polyclonal anti-LGI1 antibody (C19, 1:200; Santa Cruz Biochemicals, Santa Cruz, Calif ), and detected using a commercially available chemiluminescent substrate (SuperSignal; Pierce Chemical, Rockford, Ill).
RESULTS
CLINICAL DESCRIPTION OF THE FAMILIES WITH LGI1 MUTATIONS
All clinical examinations were performed at the Hô pital de la Pitié-Salpêtrière, Paris, France. Family A, of French origin, had 3 affected subjects, all with normal birth and psychomotor development. None had febrile seizures. The proband (I-2) was a 64-year-old right-handed man. Partial seizures began at age 11 years. He described simple partial seizures lasting 30 seconds to 1 minute consisting of bilateral buzzing sounds during which speech comprehension was impaired. No triggering factor was reported. Generalized seizures were rare. Partial seizures were frequent during the first years of the disease. At the time of the study, the patient (taking a daily regimen of 100 mg of phenytoin sodium, 10 mg of phenobarbital sodium, and 2 mg of clonazepam) had been seizure free for 4 years. His daughter (II-3), 31 years old and righthanded, had chronic depression. Epilepsy began at age 22 years with generalized tonic-clonic seizures and probable complex partial seizures with swallowing automatisms. She described no auditory symptoms. At adolescence, she started to experience dreamy states with déjà vu and déjà vécu anxiety, thoracic pressure, and sometimes sensory aphasia. She has remained seizure free since beginning treatment with antiepileptic medication (valproic acid). Her deceased sister (II-4) started to have seizures at age 24 years consisting of generalized tonicclonic seizures sometimes preceded by auditory symptoms described as bilateral buzzing sounds. Treatment with vigabatrin and valproic acid did not control the seizures, but adherence to the treatment regimen was irregular. She was depressed and committed suicide in 1996 at age 31 years. The deceased brother was also depressed and committed suicide at age 20 years. He may have had generalized tonic-clonic seizures during adolescence. Family B was of Algerian origin. Seven members were affected, but only 3 of them could be examined for the study. All 3 subjects had normal births and psychomotor development. None had febrile seizures. The proband (III-13) was a 39-year-old left-handed man. The disease began when he was 9 years old, manifested by generalized tonic-clonic seizures and partial seizures that started with the impression of hearing whistling, followed by anxiety, nausea, and a rising sensation within the body. More than 50% of his seizures were triggered by sounds, such as telephones ringing. Taking a daily regimen of 500 mg of primidone and 100 mg of phenobarbital sodium, the seizures became rare (1-2 per year). His sister (III-14) was 33 years old and right-handed. Her partial seizures began at age 10 years, manifesting as a buzzing sensation in the ears followed by loss of consciousness with gestural and verbal automatisms. Some seizures were triggered by high-pitched voices. Several antiepileptic drugs were used with little effect (carbamazepine, valproic acid, phenobarbital, and topiramate). Despite drug treatment, she continued to have several partial seizures per month, some with secondary generalization. When she was 26 years old, their 56-year-old mother (II-3) began to have complex partial seizures that were preceded by auditory symptoms and a rising sensation within the body. She has been seizure free taking a regimen of phenobarbital for the last 20 years.
IDENTIFICATION OF NOVEL LGI1 MUTATIONS
We identified 2 novel LGI1 mutations in families A and B. A c.431ϩ1GϾA substitution located in the almost invariant donor splicing site of intron 5 was found in family A ( Figure 1A) . The mutation was present in the heterozygous state in the 2 available patients ( Figure 1B) . It was not found in 170 European control subjects.
The consequences of the c.431ϩ1GϾA mutation were explored at the mRNA level. Reverse-transcriptase PCR was performed on mRNA isolated from lymphoblasts of patient II-3 and from an unrelated control subject. Polymerase chain reaction amplification of the region between exons 1 and 5 produced a single band of 398 base pairs (bp) in the control sample and an additional band of 254 bp in (REPRINTED) Figure 1C ). DNA sequencing showed that the c.431ϩ1GϾA mutation caused exons 3 and 4 to be skipped in the LGI1 transcript, confirming that the mutation is deleterious ( Figure 1D ). Because the deletion conserves the reading frame, the predicted protein should lack 48 amino acids.
In family B, a c.695t ϾC substitution was detected in exon 7 causing the leucine at position 232 to be replaced by a proline (p.Leu232Pro/L232P). The nucleotide change cosegregated in the heterozygous state with epilepsy in the 3 available patients (Figure 2A and B) . It was not found in 170 European and 84 North African control subjects. Leucine 232 is located within the second EAR and is highly conserved throughout evolution ( Figure 2C ).
p.Leu232Pro MUTATION DRAMATICALLY DECREASES LGI1 SECRETION
We then investigated the functional consequences of the p.Leu232Pro mutation in mammalian cells. We first examined the expression of exogenous LGI1 WT in the cell lysates and in the serum-free media of transiently transfected CHO cells by WB analysis. An antibody raised against the C-terminus of LGI1 recognized a band at approximately 64 kDa corresponding to FLAG LGI1 WT in the cell lysate ( Figure 3A, lane 1) . However, most LGI1 WT was found in the culture medium ( Figure 3A , lane 5), indicating that LGI1 is secreted by CHO cells.
Next, we investigated the functional consequences of LGI1 L232P and compared them with those of the previously reported LGI1 E383A mutant. 2 In the lysates, the levels of LGI1 WT , LGI1
L232P
, and LGI1
E383A were similar ( Figure 3A,  lanes 3 and 7) . However, in the culture media only LGI1 WT was detected under the exposure condition used. Similar results were obtained using the anti-FLAG antibody that recognizes the N-terminus of the protein (data not shown). The absence of mutant LGI1 in the culture media was not due to inefficient transcription or mRNA instability because mRNA of all 3 constructs was similarly reverse transcribed and amplified ( Figure 3A, middle panel) .
Because protein trafficking in CHO and neuronal cells may differ, we explored the secretion of LGI1 in the neuronlike PC12 cell line. Figure 3B shows 
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L232P AND LGI1 E383A ARE NOT PREFERENTIALLY DEGRADED BY THE PROTEASOME PATHWAY We hypothesized that the reduced extracellular levels of LGI1 mutants might have resulted from accelerated degradation by the ubiquitin-proteasome system, the main cellular pathway for the degradation of proteins. To verify this hypothesis, transfected CHO cells were grown in the presence of the proteasome inhibitor epoxomicin. Western blot analysis of cell lysates showed that LGI1 WT , LGI1
L232P
, and LGI1 E383A accumulated in the cells, indicating that the proteasome inhibitor prevented their degradation. However, it did not rescue the levels of secreted mutant proteins (Figure 4) . Although wild-type and mutant LGI1 are normally degraded by the proteasome pathway, this does not explain the decreased secretion of the mutant proteins.
COMMENT
In this study, we identified 2 novel disease-linked mutations (c.431ϩ1GϾA and p.Leu232Pro) in 2 of 6 families with ADLTE. The frequency of the mutations was similar to that in other investigations in which 30% to 50% of families with ADLTE had LGI1 mutations. 5 The clinical characteristics of our patients were consistent with previous descriptions of families with ADLTE (Table) . Patient II-3 in family A had unusual ictal symptoms with dé jà vu and dé jà vé cu suggesting involvement of the medial temporal lobe. In family A, all patients with epilepsy had psychiatric disturbances, but we could not determine whether they are caused by the same mutation as epilepsy. The course of the disease was variable within families in terms of the presence of a triggering factor, type of seizure, and pharmacosensitivity. 
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Gallus gallus We also demonstrated that the c.431 ϩ 1GϾA mutation alters mRNA splicing and leads to the in-frame deletion of exons 3 and 4 of the LGI1 transcript. The predicted truncated protein lacks 48 amino acids in the leucine-rich repeat region, which might affect interactions between LGI1 and other proteins. However, we cannot exclude that the mutant mRNA is degraded and that haploinsufficiency of LGI1 causes the disease.
We also studied the functional consequences of the p.Leu232Pro mutation in transfected mammalian cells and compared them with those of the previously described p.Glu383Ala mutation known to decrease secretion of the protein. 12 Both mutations are located in an EAR motif; the p.Leu232Pro mutation is located in the second EAR of the protein, whereas p.Glu383Ala affects a glutamic acid in the fourth EAR of the protein. In CHO cell cultures, we showed that the p.Leu232Pro mutation prevented the secretion of
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LGI1 L232P + 1µM Epoxomicin the protein into the culture medium, suggesting that a loss of function underlies the pathogenesis of LGI1-mediated epilepsy. Because we could not restore secretion by inhibiting the proteasomal degradation pathway, lack of secretion rather than loss of the protein seems to be responsible. However, we cannot exclude that mutant LGI1 L232P was degraded by extracellular proteases or was associated with the cell membrane and was not recovered with the detergents used.
These experiments provide evidence that overexpressed LGI1 is secreted by CHO and PC12 cells, confirming previous observations in 293T cells. 11, 12 Our findings suggest that the c.431 ϩ 1GϾA and p.Leu232Pro mutations lead to loss of function by different mechanisms, with the c.431ϩ1GϾA mutation leading to a truncated or missing protein and the p.Leu232Pro mutation leading to loss of the protein from the extracellular compartment where it appears to act.
The pathogenic mechanism for LGI1-mediated epilepsy has not yet been elucidated. LGI1 was reported to modulate the properties of a potassium channel through protein-protein interactions with the intracellular domains 13 and to be secreted in heterologous cells. 11, 12 This apparent paradox could be explained by the recent identification of 2 isoforms of LGI1 in the brain, 11 one of which might be secreted, whereas the other might act within the cell, as is the case for the alternatively spliced forms of dectin-1 (dectin-1E isoform is cytosolic, whereas dectin-1A is secreted). 15 In addition, the observation that LGI1 is also expressed in areas that do not express voltage-gated potassium channel subunit Kv1.1 13 suggests that LGI1 has functions in addition to the modulation of this channel. Recently, Fukata and collaborators 16 showed that ADAM22, a transmembrane protein, serves as a receptor for LGI1. In addition, application of LGI1 in hippocampal slices enhances AMPA alpha-amino 3-hydroxyl-5-isoxzolepropionate receptor-mediated synaptic transmission. Role of the Sponsor: The sponsor of the study had no role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, or in the preparation, review, or approval of the manuscript.
